Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Congressional obstacle for Reagan-Udall Foundation

Executive Summary

Rep. Rosa DeLauro (D-Conn.) is asking FDA to stop all activities related to the creation of the Reagan-Udall Foundation until policies are established that safeguard against industry influence. The foundation was established by the FDA Amendments Act to advance the agency's Critical Path initiative and identify unmet scientific needs, but is currently unfunded. In a letter to FDA Nov. 1, DeLauro expresses concern that Critical Path activities, including those by the Reagan-Udall Foundation, could lead to the "approval of drugs and devices based on lower standards for safety and efficacy, and without appropriately designed clinical trials." The congresswoman further suggests that funds for the foundation be withheld until other FDA initiatives are fully funded...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS048963

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel